Production insulin
Article reserved for subscribers
The very profitable Danish company will invest 2.1 billion euros to develop its only French factory. 500 jobs should be created by 2028 to strengthen the production of drugs against diabetes and obesity.
Treatments for diabetes and obesity are clearly not in crisis. The Danish laboratory Novo Nordisk will invest, over the next five years, 2.1 billion euros in its production site in Chartres, in Eure-et-Loir. The announcement will be made officially this Thursday, November 23 at the end of the afternoon by Emmanuel Macron, who will be on site, accompanied by the Ministers of Health, Aurélien Rousseau, and of Industry, Roland Lescure. During his visit, for which he will have worn the white coat and cap required in this type of factory, the Head of State should return to the theme of reindustrialization and medical sovereignty. The opportunity to make another big splash, after the launch of an ambitious plan around the creation of electric battery “mega-factories” in May, in Dunkirk, which attracted 6.7 billion euros. euros of foreign investment.
The Covid-19 epidemic has shown that a number of drugs,